Keyword: Imfinzi (durvalumab)
AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial should do just that, one analyst says.
With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow, and thereafter."
Key non-oncology meds came up big for AstraZeneca in Q3—but that's not what analysts wanted to talk about on the earnings conference call.
Keytruda's stumble in multiple myeloma has prompted the FDA to halt recruitment in Roche's Tecentriq tests in that cancer.
ESMO's research slate included some truly late-breaking data, plus numbers from some closely watched trials. Here's your need-to-know.
In May, AstraZeneca said its Imfinzi kept cancer at bay in the lung-cancer maintenance setting. And now, the company is unveiling by just how long.
Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.
After a disappointing combo announcement that knocked nearly 16% off of shares, AstraZeneca’s immuno-oncology portfolio needed a boost—and it got one Monday.
In the aftermath of its Mystic data release, AstraZeneca found a champion Thursday in Neil Woodford, the prominent U.K. fund manager.
AstraZeneca has made yet another controversial deal, trading half of Lynparza's profits to Merck in an $8.5B immuno-oncology collaboration.